CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,230,845
- in 7 filings, $1.6M under 10b5-1 plans
Net −$2,230,845. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 37 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-10-28 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −650 | $29.11 | $19K | 0 |
| 2024-10-28 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −6,250 | 173,806 | ||
| 2024-10-18 | Patel Anish CHIEF OPERATING OFFICER | Sale 10b5-1 | −716 | $30.00 | $21K | 343,311 |
| 2024-10-18 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −847 | $30.00 | $25K | 1,015,188 |
| 2024-10-18 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −924 | $30.00 | $28K | 1,002,892 |
| 2024-10-18 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +814 | $2.48 | $2K | 814 |
| 2024-10-18 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −814 | $30.00 | $24K | 0 |
| 2024-10-18 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −814 | 180,056 | ||
| 2024-10-18 | Heyman Richard A. Director | Sale 10b5-1 | −817 | $30.00 | $25K | 123,673 |
| 2024-10-18 | Heyman Richard A. Director | Sale 10b5-1 | −753 | $30.00 | $23K | 27,165 |
| 2024-10-18 | Collins Helen Louise CHIEF MEDICAL OFFICER | Option exercise 10b5-1 | +816 | $2.48 | $2K | 816 |
| 2024-10-18 | Collins Helen Louise CHIEF MEDICAL OFFICER | Sale 10b5-1 | −816 | $30.00 | $24K | 0 |
| 2024-10-18 | Collins Helen Louise CHIEF MEDICAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −816 | 266,268 | ||
| 2024-10-15 | Heyman Richard A. Director | Sale 10b5-1 | −1,270 | $27.67 | $35K | 124,490 |
| 2024-10-09 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −34,289 | $28.12 | $964K | 1,019,624 |
| 2024-10-09 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −3,589 | $28.52 | $102K | 1,016,035 |
| 2024-10-09 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −13,880 | $28.07 | $390K | 1,006,646 |
| 2024-10-09 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −2,830 | $28.53 | $81K | 1,003,816 |
| 2024-10-08 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −13,167 | $27.96 | $368K | 1,054,013 |
| 2024-10-08 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −100 | $28.51 | $3K | 1,053,913 |
Page 15 of 37 · 724 trades